Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.69 USD | +3.99% | +4.20% | -4.07% |
17/04 | Deutsche Bank Upgrades Medical Properties Trust to Hold From Sell, Adjusts PT to $5 From $2 | MT |
15/04 | Sector Update: Financial Stocks Sliding Late Afternoon | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 8.71 and 8.21 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.07% | 2.73B | C | ||
+5.45% | 55.76B | A- | ||
-10.69% | 17.72B | A- | ||
-3.13% | 13.23B | A | ||
+0.91% | 7.68B | B | ||
-17.93% | 5.39B | B- | ||
+9.87% | 3.28B | C- | ||
-0.53% | 3.23B | C+ | ||
-3.14% | 3.06B | B+ | ||
+13.34% | 2.73B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MPW Stock
- Ratings Medical Properties Trust, Inc.